6880 Federal Register / Vol. 87, No. 25 / Monday, February 7, 2022 / Notices 

created an immense public health, 

social, and economic burden. Variants 

of concern continue to emerge that have 

increased transmissibility, 

pathogenicity, or both and that reduce 

the effectiveness of current therapeutics 

and vaccines. Thus, there is a great need 

for broadly protective therapeutics. 

This technology relates to two 

monoclonal antibodies targeting the 

spike protein of SARS–CoV–2 that 

between the two have picomolar activity 

against wild-type SARS–CoV–2 and the 

Alpha, Beta, Delta, and Omicron 

variants of concern. Additionally, one of 

the antibodies recognizes a highlyconserved epitope of the spike protein. 

Treatment with either monoclonal 

antibody before or after challenge with 

SARS–CoV–2 reduced symptoms and 

viral load in nasal turbinate and lung 

tissue in the golden Syrian hamster 

model. This monoclonal antibody 

technology has great potential to treat 

SARS–CoV–2 infections and may 

provide protection against future 

variants of concern. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Potential Commercial Applications 

• Treatment for SARS–CoV–2 infection 

• Prophylaxis treatment to prevent or 

reduce SARS–CoV–2 infection 

• Diagnostic for SARS–CoV–2 infection 

Competitive Advantages 

• Broad and potent neutralization of 

several variants of concern, including 

Omicron 

Development Stage 

• In vivo data assessment (animal) 

Inventors: Zhaochun Chen (NIAID); 

Patrizia Farci (NIAID); Kamille West 

(CC); Peng Zhang (NIAID); Paolo Lusso 

(NIAID); Ulla Buchholz (NIAID); 

Yumiko Matsuoka (NIAID). 

Intellectual Property: HHS Reference 

No. E–132–2021– U.S. Provisional 

Application No. 63/296,380, filed 

January 4, 2022. 

Licensing Contact: To license this 

technology, please contact Elizabeth 

Pitts, Ph.D., 240–669–5299; 

elizabeth.pitts@nih.gov, and reference 

E–132–2021. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Elizabeth Pitts, Ph.D., 240–669– 

5299; elizabeth.pitts@nih.gov. 

Dated: February 1, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–02466 Filed 2–4–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NST 1 Member SEP. 

Date: March 1, 2022. 

Time: 9:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: William C. Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS, NIH, NSC, 6001 Executive 

Boulevard, Suite 3204, MSC 9529, Rockville, 

MD 20852, 301–496–0660, benzingw@

mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; BRAIN Initiative: TeamResearch BRAIN Circuit Programs U19 

Review. 

Date: March 8–11, 2022. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Tatiana Pasternak, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Boulevard, 

Suite 3208, MSC 9529, Rockville, MD 20852, 

301–496–9223, tatiana.pasternak@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Biomarkers for the Lewy 

Body Dementias. 

Date: March 11, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Joel A. Saydoff, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Boulevard, 

Room 3205, MSC 9529, Rockville, MD 20852, 

301–496–9223, joel.saydoff@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: February 1, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–02468 Filed 2–4–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2020–0016] 

Plan of Action To Establish a National 

Strategy for the Coordination of 

National Multimodal Healthcare Supply 

Chains To Respond to COVID–19; 

Implemented Under the Voluntary 

Agreement for the Manufacture and 

Distribution of Critical Healthcare 

Resources Necessary To Respond to a 

Pandemic Under Section 708 of the 

Defense Production Act 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA) is 

publishing the text of one additional 

Plan of Action under the Voluntary 

Agreement for the Manufacture and 

Distribution of Critical Healthcare 

Resources Necessary to Respond to a 

Pandemic: Plan of Action to Establish a 

National Strategy for the Coordination 

of National Multimodal Healthcare 

Supply Chains to Respond to COVID– 

19. 

FOR FURTHER INFORMATION CONTACT: 

Robert Glenn, Office of Business, 


jspears on DSK121TN23PROD with NOTICES1